Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN

Jingyou Yu; Paul V. Thomas; Katherine McMahan; Catherine Jacob-Dolan; Jinyan Liu; Xuan He; David Hope; Elizabeth J. Martinez; Wei Hung Chen; Michaela Sciacca; Nicole P. Hachmann; Michelle Lifton; Jessica Miller; Olivia C. Powers; Kevin Hall; Cindy Wu; Julia Barrett; Isabella Swafford; Jeffrey R. Currier; Jocelyn King; Courtney Corbitt; William C. Chang; Emily Golub; Phyllis A. Rees; Caroline E. Peterson; Agnes Hajduczki; Elizabeth Hussin; Camille Lange; Hua Gong; Gary R. Matyas; Mangala Rao; Dominic Paquin-Proulx; Gregory D. Gromowski; Mark G. Lewis; Hanne Andersen; Meredith Davis-Gardner; Mehul S. Suthar; Nelson L. Michael; Diane L. Bolton; M. Gordon Joyce; Kayvon Modjarrad; Dan H. Barouch

doi:10.1126/sciadv.ade4433

Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN

Jingyou Yu, Paul V. Thomas, Katherine McMahan, Catherine Jacob-Dolan, Jinyan Liu, Xuan He, David Hope, Elizabeth J. Martinez, Wei Hung Chen, Michaela Sciacca, Nicole P. Hachmann, Michelle Lifton, Jessica Miller, Olivia C. Powers, Kevin Hall, Cindy Wu, Julia Barrett, Isabella Swafford, Jeffrey R. Currier, Jocelyn KingCourtney Corbitt, William C. Chang, Emily Golub, Phyllis A. Rees, Caroline E. Peterson, Agnes Hajduczki, Elizabeth Hussin, Camille Lange, Hua Gong, Gary R. Matyas, Mangala Rao, Dominic Paquin-Proulx, Gregory D. Gromowski, Mark G. Lewis, Hanne Andersen, Meredith Davis-Gardner, Mehul S. Suthar, Nelson L. Michael, Diane L. Bolton, M. Gordon Joyce^*, Kayvon Modjarrad, Dan H. Barouch^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and waning immunity call for next-generation vaccine strategies. Here, we assessed the immunogenicity and protective efficacy of two SARSCoV-2 vaccines targeting the WA1/2020 spike protein, Ad26.COV2.S (Ad26) and Spike ferritin Nanoparticle (SpFN), in nonhuman primates, delivered as either a homologous (SpFN/SpFN and Ad26/Ad26) or heterologous (Ad26/SpFN) prime-boost regimen. The Ad26/SpFN regimen elicited the highest CD4 T cell and memory B cell responses, the SpFN/SpFN regimen generated the highest binding and neutralizing antibody responses, and the Ad26/Ad26 regimen generated the most robust CD8 T cell responses. Despite these differences, protective efficacy against SARS-CoV-2 Omicron BA.1 challenge was similar for all three regimens. After challenge, all vaccinated monkeys showed significantly reduced peak and day 4 viral loads in both bronchoalveolar lavage and nasal swabs as compared with sham animals. The efficacy conferred by these three immunologically distinct vaccine regimens suggests that both humoral and cellular immunity contribute to protection against SARSCoV-2 Omicron challenge.

Original language	English
Article number	eade4433
Journal	Science Advances
Volume	8
Issue number	47
DOIs	https://doi.org/10.1126/sciadv.ade4433
State	Published - 25 Nov 2022
Externally published	Yes

Access to Document

10.1126/sciadv.ade4433

Cite this

Yu, J., Thomas, P. V., McMahan, K., Jacob-Dolan, C., Liu, J., He, X., Hope, D., Martinez, E. J., Chen, W. H., Sciacca, M., Hachmann, N. P., Lifton, M., Miller, J., Powers, O. C., Hall, K., Wu, C., Barrett, J., Swafford, I., Currier, J. R., ... Barouch, D. H. (2022). Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN. Science Advances, 8(47), Article eade4433. https://doi.org/10.1126/sciadv.ade4433

@article{fe68891268c048b8bed75d75322d11a1,

title = "Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN",

abstract = "Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and waning immunity call for next-generation vaccine strategies. Here, we assessed the immunogenicity and protective efficacy of two SARSCoV-2 vaccines targeting the WA1/2020 spike protein, Ad26.COV2.S (Ad26) and Spike ferritin Nanoparticle (SpFN), in nonhuman primates, delivered as either a homologous (SpFN/SpFN and Ad26/Ad26) or heterologous (Ad26/SpFN) prime-boost regimen. The Ad26/SpFN regimen elicited the highest CD4 T cell and memory B cell responses, the SpFN/SpFN regimen generated the highest binding and neutralizing antibody responses, and the Ad26/Ad26 regimen generated the most robust CD8 T cell responses. Despite these differences, protective efficacy against SARS-CoV-2 Omicron BA.1 challenge was similar for all three regimens. After challenge, all vaccinated monkeys showed significantly reduced peak and day 4 viral loads in both bronchoalveolar lavage and nasal swabs as compared with sham animals. The efficacy conferred by these three immunologically distinct vaccine regimens suggests that both humoral and cellular immunity contribute to protection against SARSCoV-2 Omicron challenge.",

author = "Jingyou Yu and Thomas, {Paul V.} and Katherine McMahan and Catherine Jacob-Dolan and Jinyan Liu and Xuan He and David Hope and Martinez, {Elizabeth J.} and Chen, {Wei Hung} and Michaela Sciacca and Hachmann, {Nicole P.} and Michelle Lifton and Jessica Miller and Powers, {Olivia C.} and Kevin Hall and Cindy Wu and Julia Barrett and Isabella Swafford and Currier, {Jeffrey R.} and Jocelyn King and Courtney Corbitt and Chang, {William C.} and Emily Golub and Rees, {Phyllis A.} and Peterson, {Caroline E.} and Agnes Hajduczki and Elizabeth Hussin and Camille Lange and Hua Gong and Matyas, {Gary R.} and Mangala Rao and Dominic Paquin-Proulx and Gromowski, {Gregory D.} and Lewis, {Mark G.} and Hanne Andersen and Meredith Davis-Gardner and Suthar, {Mehul S.} and Michael, {Nelson L.} and Bolton, {Diane L.} and Joyce, {M. Gordon} and Kayvon Modjarrad and Barouch, {Dan H.}",

note = "Publisher Copyright: 2022 The Authors, some rights reserved;",

year = "2022",

month = nov,

day = "25",

doi = "10.1126/sciadv.ade4433",

language = "English",

volume = "8",

journal = "Science Advances",

issn = "2375-2548",

number = "47",

}

Yu, J, Thomas, PV, McMahan, K, Jacob-Dolan, C, Liu, J, He, X, Hope, D, Martinez, EJ, Chen, WH, Sciacca, M, Hachmann, NP, Lifton, M, Miller, J, Powers, OC, Hall, K, Wu, C, Barrett, J, Swafford, I, Currier, JR, King, J, Corbitt, C, Chang, WC, Golub, E, Rees, PA, Peterson, CE, Hajduczki, A, Hussin, E, Lange, C, Gong, H, Matyas, GR, Rao, M, Paquin-Proulx, D, Gromowski, GD, Lewis, MG, Andersen, H, Davis-Gardner, M, Suthar, MS, Michael, NL, Bolton, DL, Joyce, MG, Modjarrad, K & Barouch, DH 2022, 'Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN', Science Advances, vol. 8, no. 47, eade4433. https://doi.org/10.1126/sciadv.ade4433

TY - JOUR

T1 - Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN

AU - Yu, Jingyou

AU - Thomas, Paul V.

AU - McMahan, Katherine

AU - Jacob-Dolan, Catherine

AU - Liu, Jinyan

AU - He, Xuan

AU - Hope, David

AU - Martinez, Elizabeth J.

AU - Chen, Wei Hung

AU - Sciacca, Michaela

AU - Hachmann, Nicole P.

AU - Lifton, Michelle

AU - Miller, Jessica

AU - Powers, Olivia C.

AU - Hall, Kevin

AU - Wu, Cindy

AU - Barrett, Julia

AU - Swafford, Isabella

AU - Currier, Jeffrey R.

AU - King, Jocelyn

AU - Corbitt, Courtney

AU - Chang, William C.

AU - Golub, Emily

AU - Rees, Phyllis A.

AU - Peterson, Caroline E.

AU - Hajduczki, Agnes

AU - Hussin, Elizabeth

AU - Lange, Camille

AU - Gong, Hua

AU - Matyas, Gary R.

AU - Rao, Mangala

AU - Paquin-Proulx, Dominic

AU - Gromowski, Gregory D.

AU - Lewis, Mark G.

AU - Andersen, Hanne

AU - Davis-Gardner, Meredith

AU - Suthar, Mehul S.

AU - Michael, Nelson L.

AU - Bolton, Diane L.

AU - Joyce, M. Gordon

AU - Modjarrad, Kayvon

AU - Barouch, Dan H.

PY - 2022/11/25

Y1 - 2022/11/25

N2 - Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and waning immunity call for next-generation vaccine strategies. Here, we assessed the immunogenicity and protective efficacy of two SARSCoV-2 vaccines targeting the WA1/2020 spike protein, Ad26.COV2.S (Ad26) and Spike ferritin Nanoparticle (SpFN), in nonhuman primates, delivered as either a homologous (SpFN/SpFN and Ad26/Ad26) or heterologous (Ad26/SpFN) prime-boost regimen. The Ad26/SpFN regimen elicited the highest CD4 T cell and memory B cell responses, the SpFN/SpFN regimen generated the highest binding and neutralizing antibody responses, and the Ad26/Ad26 regimen generated the most robust CD8 T cell responses. Despite these differences, protective efficacy against SARS-CoV-2 Omicron BA.1 challenge was similar for all three regimens. After challenge, all vaccinated monkeys showed significantly reduced peak and day 4 viral loads in both bronchoalveolar lavage and nasal swabs as compared with sham animals. The efficacy conferred by these three immunologically distinct vaccine regimens suggests that both humoral and cellular immunity contribute to protection against SARSCoV-2 Omicron challenge.

AB - Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and waning immunity call for next-generation vaccine strategies. Here, we assessed the immunogenicity and protective efficacy of two SARSCoV-2 vaccines targeting the WA1/2020 spike protein, Ad26.COV2.S (Ad26) and Spike ferritin Nanoparticle (SpFN), in nonhuman primates, delivered as either a homologous (SpFN/SpFN and Ad26/Ad26) or heterologous (Ad26/SpFN) prime-boost regimen. The Ad26/SpFN regimen elicited the highest CD4 T cell and memory B cell responses, the SpFN/SpFN regimen generated the highest binding and neutralizing antibody responses, and the Ad26/Ad26 regimen generated the most robust CD8 T cell responses. Despite these differences, protective efficacy against SARS-CoV-2 Omicron BA.1 challenge was similar for all three regimens. After challenge, all vaccinated monkeys showed significantly reduced peak and day 4 viral loads in both bronchoalveolar lavage and nasal swabs as compared with sham animals. The efficacy conferred by these three immunologically distinct vaccine regimens suggests that both humoral and cellular immunity contribute to protection against SARSCoV-2 Omicron challenge.

UR - http://www.scopus.com/inward/record.url?scp=85142612286&partnerID=8YFLogxK

U2 - 10.1126/sciadv.ade4433

DO - 10.1126/sciadv.ade4433

M3 - Article

C2 - 36417525

AN - SCOPUS:85142612286

SN - 2375-2548

VL - 8

JO - Science Advances

JF - Science Advances

IS - 47

M1 - eade4433

ER -

Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN

Abstract

Access to Document

Fingerprint

Cite this